Printed from Voxsanity (voxsanity.com.au) — NCT06615479 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have multiple myeloma that has come back after treatment or has stopped responding to treatment.
People who have received at least 1 but no more than 3 previous treatment courses for multiple myeloma, which may have included certain types of drugs such as a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody treatment, and who have previously been treated with a drug called lenalidomide.
People who have a confirmed diagnosis of multiple myeloma based on internationally recognised diagnostic standards.
People whose disease can be detected and measured through tests done during the screening process.
People whose heart, kidneys, liver, and other organs are functioning well enough to meet the trial's requirements.
People who are largely able to carry out daily activities, with little to no restriction from their illness (confirm with trial site for exact fitness level required).
Who may not be able to join:
People who have had, or currently have, multiple myeloma that has spread to the brain or spinal cord.
People whose myeloma presents only as an isolated tumour, or as a form that does not produce detectable proteins in the blood or urine, without other measurable signs of disease.
People who need to start treatment urgently because their myeloma is progressing very quickly.
There are additional criteria set out in the trial protocol that may also affect eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Royal Prince Alfred Hospital, Camperdown, New South Wales
+61295158031
Liverpool Hospital, Liverpool, New South Wales
0287385167
Princess Alexandra Hospital, Brisbane, Queensland
0731762111
Royal Adelaide Hospital, Adelaide, South Australia
+61 08 7074 3290
Monash Health, Clayton, Victoria
03 9594 4044
Peter MacCallum Cancer Centre, Melbourne, Victoria
61385595000
The Alfred Hospital, Melbourne, Victoria
0403374221
Fiona Stanley Hospital, Murdoch, Western Australia
+61861523788
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06615479
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: 855-907-3286
More information: https://clinicaltrials.gov/study/NCT06615479
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have multiple myeloma that has come back after treatment or has stopped responding to treatment.
People who have received at least 1 but no more than 3 previous treatment courses for multiple myeloma, which may have included certain types of drugs such as a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody treatment, and who have previously been treated with a drug called lenalidomide.
People who have a confirmed diagnosis of multiple myeloma based on internationally recognised diagnostic standards.
People whose disease can be detected and measured through tests done during the screening process.
People whose heart, kidneys, liver, and other organs are functioning well enough to meet the trial's requirements.
People who are largely able to carry out daily activities, with little to no restriction from their illness (confirm with trial site for exact fitness level required).
Who may not be able to join:
People who have had, or currently have, multiple myeloma that has spread to the brain or spinal cord.
People whose myeloma presents only as an isolated tumour, or as a form that does not produce detectable proteins in the blood or urine, without other measurable signs of disease.
People who need to start treatment urgently because their myeloma is progressing very quickly.
There are additional criteria set out in the trial protocol that may also affect eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Registry
ClinicalTrials.gov
Start date
12 March 2025
Est. completion
30 December 2027
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇮 Finland
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇵🇹 Portugal
🇷🇴 Romania
🇸🇦 Saudi Arabia
🇸🇬 Singapore
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇹🇼 Taiwan
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.